Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference
November 16 2022 - 8:30AM
Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad
pipeline targeting cancer and infectious disease, today announced
that Dr. Garo Armen, Chairman and CEO of Agenus, and Dr. Steven
O’Day, Chief Medical Officer, will participate in a virtual
fireside chat at the 5th Annual Evercore ISI HealthCONx Conference
on Wednesday, November 30th at 12:35pm ET. The Conference will be
held virtually from November 29th – December 1st, during which
Agenus will host one-on-one meetings with investors.
Registration for the webcast can
be accessed at https://wsw.com/webcast/evercore29/agen/2333250.
Following the webcast, an archived version will be available
on the Investors section of the Agenus website at
https://investor.agenusbio.com/events-and-presentations.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer and
infections. The Company's vision is to expand the patient
populations benefiting from cancer immunotherapy by pursuing
combination approaches that leverage a broad repertoire of antibody
therapeutics, adoptive cell therapies (through its subsidiary MiNK
Therapeutics), and adjuvants (through its subsidiary SaponiQx). The
Company is equipped with a suite of antibody discovery platforms
and a state-of-the-art GMP manufacturing facility with the capacity
to support clinical programs. Agenus is headquartered in Lexington,
MA. For more information, please visit www.agenusbio.com and our
Twitter handle @agenus_bio. Information that may be important to
investors will be routinely posted on our website and Twitter.
ContactAgenus Inc.Nico FrelickInvestor
Relations781-674-4616Nico.frelick@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024